Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 15, 2025

Uterine Fibroid Drugs Market Set to Reach US$ 12.8 Billion by 2035 | Astute Analytica

View original at globenewswire.com
Uterine Fibroid Drugs Market Set to Reach US$ 12.8 Billion by 2035 | Astute Analytica Chicago, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Approximately 80% of women with fibroids may be asymptomatic

    80% confidence

  • Sumitomo Pharma's revised revenue forecast for its North American segment is JPY 248.2 billion for the fiscal year ending March 2025

    80% confidence

  • AbbVie expects combined sales of its immunology duo to exceed US$ 27 billion in 2027

    80% confidence

  • Sumitomo Pharma expects to receive a significant US$ 100 million sales milestone payment from Pfizer in the upcoming fiscal year

    80% confidence

  • Sumitomo projects JPY 98.9 billion in net profit attributable to owners for the half-year ended September 30, 2025

    80% confidence

  • Kissei's 2025 forecast includes a JPY 13.2 billion upward revision in core operating profit

    80% confidence

  • Sumitomo has allocated JPY 13 billion for R&D expenses in FY2025

    80% confidence

  • The global age-standardized incidence rate reached 250.93 per 100,000 in the 2025 reporting period

    80% confidence

  • The global uterine fibroid drugs market was valued at US$ 3.8 billion in 2025 and is expected to reach US$ 12.8 billion by 2035, growing at a CAGR of 14.4% during the forecast period 2026–2035

    80% confidence

  • Clinical efficacy data showing 78 percent blood loss reduction

    80% confidence

  • Their immunology division generated US$ 26.682 billion

    80% confidence

  • 25% to 50% of symptomatic women fall into the critical 30-50 age bracket

    80% confidence

  • Sumitomo Pharma recorded a JPY 1.6 billion gain in Q3 FY2024 specifically from equity transfers

    80% confidence

  • The company forecasts JPY 28.8 billion in operating profit for the fiscal year ending March 2025

    80% confidence

  • The company expects a JPY 19.9 billion revenue increase from Orgovyx

    80% confidence

  • Sumitomo Pharma reported a volume underperformance of US$ 37 million for Myfembree in the U.S. for the period ending December 2024

    80% confidence

  • Myfembree revenue is expected to remain flat in FY2025 during the sales model transition

    80% confidence

  • Sumitomo forecasts a core operating profit of JPY 56 billion for FY2025

    80% confidence

  • Sumitomo Pharma projects FY2025 revenue to reach JPY 429 billion based on the October 2025 revised forecast

    80% confidence

  • AbbVie issued confident 2025 adjusted diluted EPS guidance between US$ 12.12 and US$ 12.32

    80% confidence

  • AbbVie reaffirms a high single-digit compound annual revenue growth rate for its ex-Humira platform through 2029

    80% confidence

  • AbbVie reported substantial full-year 2024 net revenues of US$ 56.334 billion

    80% confidence

  • A comprehensive 2024 analysis estimates the total annual economic burden of uterine fibroids in the US at up to US$ 41.4 billion

    80% confidence